Quarry LP Buys 3,108 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Quarry LP lifted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 47.8% during the 2nd quarter, Holdings Channel reports. The firm owned 9,608 shares of the company’s stock after buying an additional 3,108 shares during the quarter. Quarry LP’s holdings in Centessa Pharmaceuticals were worth $87,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in CNTA. Trexquant Investment LP bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $114,000. Platinum Investment Management Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 12.9% during the fourth quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after purchasing an additional 43,539 shares during the last quarter. Octagon Capital Advisors LP increased its stake in shares of Centessa Pharmaceuticals by 333.2% in the fourth quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock valued at $16,398,000 after buying an additional 1,584,500 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 69.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after buying an additional 4,423 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Centessa Pharmaceuticals during the 1st quarter worth about $330,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

CNTA opened at $16.26 on Thursday. The company has a fifty day moving average price of $13.41 and a two-hundred day moving average price of $10.96. The firm has a market capitalization of $1.63 billion, a PE ratio of -11.45 and a beta of 1.44. Centessa Pharmaceuticals plc has a 52 week low of $5.15 and a 52 week high of $17.59. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, analysts anticipate that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.53, for a total value of $909,150.00. Following the sale, the chief executive officer now directly owns 721,924 shares in the company, valued at approximately $11,933,403.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $16.53, for a total value of $909,150.00. Following the completion of the sale, the chief executive officer now owns 721,924 shares in the company, valued at approximately $11,933,403.72. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total value of $375,000.00. Following the sale, the insider now directly owns 223,369 shares in the company, valued at approximately $3,350,535. The disclosure for this sale can be found here. In the last ninety days, insiders sold 288,492 shares of company stock worth $4,641,902. 11.59% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Jefferies Financial Group boosted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Guggenheim boosted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. BMO Capital Markets increased their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and an average price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.